ABM Therapeutics presented Medicilon with a commemorative trophy of "our first candidate compound"

On October 31, 2020, ABM Therapeutics awarded the "Our First Candidate Compound" commemorative trophy to Dr. Li Zhigang, Vice President of Research and Development of Medicilon Chemistry Department, to thank Medicilon for its FTE form of cooperation, the pharmaceutical and chemical team helped it discover and advance the first drug candidate ABM-1310 to enter the clinical phase I in the United States.

ABM-1310 is a new generation of BRAF inhibitor independently developed by ABM Therapeutics, which has an ideal blood-brain barrier permeability. In animal experiments, the brain-free concentration of ABM-1310 reached 100%. At the same time, in related brain metastases and brain orthotopic animal models, its test data is significantly better than the first BRAF inhibitor Erlotinib approved by the US FDA in 2011, and the median survival time is prolonged by the same dose of ABM-1310 doubled.

ABM-1310 obtained clinical trial approval from the U.S. Food and Drug Administration (FDA) on November 29, 2019, and started a phase I clinical trial, recruiting patients with BRAF V600E/K gene mutations, and at MD Anderson Cancer Center in the U.S. start up. New drug research and development is a highly complex subject that requires a lot of time and capital investment. Every choice from the beginning of project approval will determine the ultimate success or failure of a new drug. Medicilon is committed to assisting innovative R&D companies, adhering to the service concept of "innovation-driven, quality first", providing a full range of new drug preclinical R&D services for large domestic pharmaceutical companies and many emerging well-known innovative biotechnology companies.

The Medicilon FTE team that cooperates with ABM Therapeutics in this cooperation is from the Medicilon Chemistry Department and belongs to the Medicilon drug discovery. Drug discovery is the initial stage of drug development. Through early research, select and confirm the gene function and target of the target disease, screen and optimize lead compounds, and conduct early safety screening, drug modification and other druggability research to obtain drugs with druggable candidate compounds. Medicilon's drug discovery R&D services include protein target validation, structural biology, chemical synthesis, compound activity screening and optimization, etc.

Medicilon congratulates ABM Therapeutics on this phased victory, and wishes ABM-1310 and other projects to progress smoothly. At the same time, domestic and foreign innovative pharmaceutical companies are also welcome to cooperate with Medicilon on R&D projects. Medicilon will integrate R&D strength and provide all-round support and cooperation!

Contact us 

Email: marketing@medicilon.com